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Abstract 
Background: Apoptotic neuronal death is known as programmed cell death. Inhibition of this progression might 
contribute to a new treatment strategy. However, methods for in vivo detection of live apoptotic cells are in need to 
be developed and established.
Context and purpose: The purpose of this study is to develop a new method for in vivo brain imaging for live 
apoptotic lesions using magnetic resonance imaging (MRI). We focused on the specific accumulation of our recently 
developed functional magnetic nanoparticles (FMNPs) into apoptotic cells using a rat cerebral ischemia model. Sul-
phorhodamine B, fluorescent dye was linked to valylalanylaspartic acid fluoromethyl ketone as a pan-caspase inhibi-
tor to form SR-FLIVO. SR-FLIVO was bound with FMNPs to develop SR-FLIVO-FMNP probe. Ischemic rat brains were 
scanned by 7T MRI before and after intravenous injection of SR-FLIVO-FMNP and the distribution was evaluated by 
subtraction images of T2* colored mapping. SR-FLIVO, intracellular FMNPs, and T2* reduction area were histologically 
analyzed. The distribution of SR-FLIVO-FMNP was evaluated by subtracting the T2* signal images and was significantly 
correlated with the histological findings by TUNEL staining.
Results: Our experimental results revealed several findings where our newly developed probe SR-FLIVO-FMNP was 
intravenously administered into ischemic rats and FLIVO expression was tracked and found in apoptotic cells in rat 
brains after cerebral ischemia. A remarkable T2* reduction within the ischemic lesion was recorded using MRI based 
SR-FLIVO-FMNP probe as a contrasting agent due to the specific probe accumulation in apoptotic cells whereas, no 
observation of T2* reduction within the non-ischemic lesion due to no probe accumulation in non-apoptotic cells. 
Histological analysis based on the correlation between FLIVO and TUNEL staining showed that almost all FLIVO-posi-
tive cells were positive for TUNEL staining. These findings suggest the possibility for establishment of in vivo targeting 
delivery methods to live apoptotic cells based on conjugation of magnetic and fluorescent dual functional probes.
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Background
Apoptosis plays a key role in the pathogenesis of a variety 
of disorders including cerebral and myocardial ischemia, 
autoimmune and neurodegenerative diseases, infections, 
organ and bone marrow transplant rejection, and tumor 
response to chemotherapy and/or radiotherapy [1, 2]. At 
present, non-invasive techniques for direct in vivo detec-
tion of apoptotic cells are quite rare and urgently need 
improvement. Early in  vivo detection of apoptotic cells 
can provide the physician with important information to 
develop further therapeutic strategies in chemotherapy 
or radiotherapy of tumors, in transplantation of organs, 
or in rescue of ischemic areas [2]. However, there are few, 
if any, reagents are currently available to assess the occur-
rence of apoptosis in living tissue.
Previously, several attempts had been carried out to 
detect apoptosis using different imaging techniques. Via 
microscopy, Zhang et al. [3] reported the conjugation of 
Annexin V with polyethylene glycol-coated core cross 
linked polymeric micelles (CCPMs) labeled with (111In) to 
form A5-CCPM for dual SPECT and optical microscopic 
detections. However, short blood life time of Annexin 
A5 makes the time point of assessment very critical to 
be monitored. Meanwhile, the inversion of phosphatidyl-
serine may not be exclusively related to apoptosis and 
this adds to the background issues [4–7]. Yivgi-Ohana 
et  al. [8] used fluorescence microscopy to examine the 
in vivo apoptosis expression of split yellow fluorescence 
protein (YFP) fragments in liver hepatocytes.
In clinical diagnostics, MRI is considered as the most 
powerful non-invasive imaging tool. Since MRI tech-
nique has a relatively higher spatial resolution than pre-
viously reported techniques such as magnetic resonance 
spectroscopy (MRS) and radionuclide techniques, thus; 
it could show better detection for apoptotic lesions aided 
with suitable contrasting agent [9, 10]. The key features 
for apoptosis detection mainly depend on the detection 
of phosphatidylserine derivatives or activated caspases. 
Several studies reported the usage of different probes as 
MRI contrasting agents to detect apoptosis based on the 
conjugation of these developed probes with phosphati-
dylserine derivatives located on the surface of the cell 
membrane [11–13].
We focused on a new fluorescent dye-conjugated 
apoptotic detector, FLIVO (fluorescence in  vivo). This 
effective moiety is composed of a polycaspase inhibitor, 
SR-Val-Ala-Asp-fluoromethyl ketone (SR-VAD-FMK), 
and sulphorhodamine B. SR-VAD-FMK is a well-known 
inhibitor that irreversibly binds to the catalytic site of 
caspase proteases and can be delivered specifically into 
apoptotic neuronal cells intravenously after stroke [14– 
16]. FLIVO has been shown to have characteristics that 
are useful for an in  vivo apoptotic marker, such as gen-
eral solubility, cell permeability into the blood–brain 
barrier (BBB), long plasma circulation (30–60  min) and 
the ability to form covalent bonds with the active site of 
the cysteine-dependant aspartate-specific protease (cas-
pases) enzyme. In addition, the free or unbound probe is 
readily removed from cells [14–17].
Nanotechnology, as it relates to biomedicine, can be 
broadly defined as nano-sized structures that have at 
least one dimension between 1 and 100 nm and exhibit 
new or enhanced properties that are unattainable at both 
smaller and larger levels [18]. The therapy and diagno-
sis (theranostics) of pathologies that affect the central 
nervous system are currently undergoing a renaissance 
because of the marked proliferation of nanoscale tech-
nologies [19]. Several nanomaterials have been used as 
platforms for the theranostics of stroke showing prom-
ising research results that could be applicable in future 
clinical applications once completed and approved [20, 
21]. USPIO are based on magnetite, which has received 
much attention for biomedical applications, or magh-
emite molecules encased in polysaccharide, synthetic 
polymers, or monomer coatings [20–22].
The utility of magnetic iron oxide nanoparticles 
(MNPs) as a magnetic resonance imaging (MRI) contrast 
agent has been studied for more than two decades [18, 
19]. Iron oxide MNPs that possess a diameter between 
10 and 50 nm are classified as ultra-small superparamag-
netic particles of iron oxide (USPIO). USPIO is known to 
be permeable to the BBB and are taken up by monocytes 
and macrophages after intravenous administration [19–
22]. USPIO tend to be applied more in magnetic suscep-
tibility-based acquisitions in T2- or T2*-weighted MRI, 
in which they produce a hypointense signal [19].
There is a great deal of interest in developing multi-
modality probes for molecular imaging [22–24]. Mag-
netic iron oxide nanoparticles have been widely studied 
for biological and biomedical applications owing to their 
Conclusion: A newly developed probe SR-FLIVO-FMNP might be considered as a useful probe for in vivo apoptotic 
detection, and FMNPs might be a strong platform for noninvasive imaging and targeting delivery.
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useful magnetic properties [25, 26]. MNPs effectively 
reduce the proton relaxation time in MRI and hence, lead 
to decreases in T1, T2, and T2* quantities [22]. It should 
be noted that the transverse relaxivity (T2 and T2*) of 
MNP contrast agents is far greater than their longitudi-
nal relaxivity (T1), which explains why MNPs are used 
mainly as negative agents for T2/T2*-weighted imaging 
[27, 28].
In this study, we aimed to develop a new method for 
in vivo targeting delivery for live apoptotic lesions in the 
ischemic brain and for image tracking by MRI. For the 
first time, a multifunctional apoptotic detecting probe, 
SR-FLIVO-FMNP, was fabricated by binding sulph-
forhodamine B, fluorescent dye-conjugated FLIVO, with 
functionalized Fe2O3 MNPs. In vivo apoptotic neuronal 
cell death in ischemic rat brains was induced by an estab-
lished transient focal cerebral ischemia (tFCI) model [29, 
30]. We report the effectiveness and promise of this new 
probe of live neuronal apoptotic cells in rat brains after 
cerebral ischemia using MRI.
Methods
Fabrication of SR‑FLIVO‑FMNP
Synthesis of Fe2O3 MNPs, surface fictionalization and 
conjugation to SR-FLIVO was carried out as previously 
described [31]. Breifly, 5.0 g of 0.15 mM FeCl2·4H2O was 
mixed with 0.5 mL of 1.0 M HCl at room temperature for 
5 min. to form solution A. 1.2 g CTAB was dissolved with 
10 mL n-Octane followed by addition of 10 mL 1-butanol 
and stirring at 40 °C for 20 min to form solution B. Solu-
tions A and B were mixed together under vigorous stir-
ring for 30 min at 40  °C followed by addition of 6.0 mL 
of 0.25  M NaOH and kept under stirring for another 
20  min to produce microemulsion of Fe2O3 nanoparti-
cles. Decantation and then centrifugation carried out and 
finally the NP supernatant was washed thoroughly with 
water and acetone and kept for drying.
For silica-shell coating iron oxide core, a starting sol 
contains an equi-molar of Na2SiO3·9H2O:FeCl2·4H2O as 
silica and iron sources, respectively was used under the 
same mentioned conditions. Removal of the hexadecyl-
trimethylammonium bromide (CTAB) surfactant was 
carried out using solvent extraction method where NPs 
(Fe2O3 and Fe2O3–SiO2) were immersed in hot ethanol 
at 50  °C for 20 h. Finally the surface grafting with -NH2 
group for Fe2O3–SiO2 NPs was carried out using 3-Ami-
nopropyltriethoxysilane (APTES) by immersing 1.0  g of 
the NPs in 20 % APTES/Toluene mixture and allowed to 
interact for 12 h at 50 °C followed by washing thoroughly 
with ethanol and hexane. Formation of SR-FLIVO-
FMNP was carried out using 1.0 mg of FNPs/1.0 mL of 
SR-FLIVO.
Rat cerebral ischemia model
Animal experimental procedures were conducted accord-
ing to the guidelines established and approved by Animal 
Care Committee at Tohoku University. Animal arrive 
guidelines were followed in the preparation of the manu-
script. Adult male rats (3  months old, 260–290  g) were 
subjected to tFCI by intraluminal MCA blockade with a 
nylon suture as described previously [30]. The rats were 
anesthetized with 1.5  % isoflurane in 30  % oxygen and 
70 % nitrous oxide using a face mask. The rectal tempera-
ture was controlled at 37 °C. Blood gas was analyzed with 
a pH/blood gas analyzer (Chiron Diagnostics Ltd). After 
a midline skin incision, the left external carotid artery 
was exposed and its branches were electrocoagulated. 
A 22.0  mm 3–0 surgical monofilament nylon suture, 
blunted at the end, was introduced into the left internal 
carotid artery through the external carotid artery stump. 
After 90  min of middle cerebral artery occlusion, blood 
flow was restored by the withdrawal of the nylon suture. 
For probe (bare FMNP or SR-FLIVO-FMNP, n = 4 each) 
administration, the left jugular vein was exposed between 
the sternocleidomastoid muscle and anterior perusal 
muscle. 100  μg of SR-FLIVO were diluted in 50  μl of 
DMSO followed by addition of 200 μl of PBS buffer. The 
volume ratio of DMSO/PBS buffer was kept 1:5. The left 
jugular vein was cannulated with a 23–gauge needle and 
600 μl of SR-FLIVO-FMNP or bare FMNP/PBS (1.0 mg/
ml) solution was injected and kept in blood circulation 
for 60 min before MRI signal recording.
Histochemical analyses
Methods of staining and immunohistochemical assess-
ment were according to the previously described in Saito 
et al. [1] Anesthetized animals, as well as normal controls 
(n =  4 each), were perfused with 10  U/ml heparin and 
subsequently with 4  % paraformaldehyde in 0.1  M PBS 
(pH 7.4) at 8, 12 and 24 h of reperfusion. The brains were 
removed, post-fixed for 12  h and sectioned to 50  μm 
using vibratome (Leica VT1000S). Immunohistochemis-
try was performed using the avidin–biotin technique and 
then the nuclei were counterstained with methyl green 
solution for 2 min, or fluorescein isothiocyanate or Texas 
Red-conjugated secondary antibody. For histological 
assessment, alternate slices from each brain section were 
stained with hematoxylin and eosin or cresyl violet.
Histological detection of apoptosis
To clarify the spatial distribution of apoptotic cells after 
cerebral ischemia, we performed terminal deoxynucle-
otidyl transferase-mediated uridine 5′-triphosphate-
biotin nick end labeling (TUNEL) staining as previously 
described (n = 8 each) [1]. Fixed sections were incubated 
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with NeuroPore (Trevigen) for 30 min. They were placed 
in 1  ×  terminal deoxynucleotidyl transferase (TdT) 
buffer (Invitrogen) with a TdT enzyme (Invitrogen) and 
biotinylated 16-dUTP (Roche Diagnostics) at 37  °C for 
90  min. The avidin–biotin technique was applied and 
then the nuclei were counterstained with methyl green 
solution for 2 min. For more precise confirmation about 
SR-FLIVO-FMNP probe tracking within the apoptotic 
cells, high resolution transmission electron microscopy 
(HRTEM) was recorded for the cells located at ischemic 
and non-ischemic lesions.
MRI measurements
Each rat was initially anesthetized with 5  % isoflurane. 
All MRI data were acquired using a 7T Bruker Phar-
maScan system (Bruker Biospin, Ettlingen, Germany) 
with a 38-mm-diameter birdcage coil. T2* mappings 
were obtained using a respiratory-gated multiple gradi-
ent echo (MGE) imaging sequence with the following 
parameters: TR =  1500  ms, TE =  4, 11, 18, 25, 32, 39, 
46, 53, 60, 67, 74, and 81  ms, flip angle =  20°, field-of-
view = 32 × 32 mm2, matrix size = 200 × 200, in-plane 
resolution = 160 × 160 um2, slice thickness = 1 mm, slice 
gap = 0 mm, number of slices = 16, and number of aver-
ages = 4. T2-weighted anatomical images were obtained 
using a respiratory-gated 2D TurboRARE sequence 
with fat suppression under the following parameters: 
TR  =  4000  ms, TEeff  =  36  ms, RARE factor  =  8, flip 
angle  =  90°, field-of-view  =  32  ×  32  mm2, matrix 
size = 200 × 200, in-plane resolution = 160 × 160 um2, 
slice thickness  =  1  mm, slice gap  =  0  mm, number of 
slices = 16, and number of averages = 10. MGE images 
were analyzed using custom-written software, MATLAB 
(R2009b; MathWorks). The analytical procedures have 
been previously described [32]. T2* reduction maps were 
derived from the simple T2* value subtraction in a voxel-
by-voxel manner (i.e., T2*post inj.–T2*pre inj.). The MRI 
phantom was constructed from 1  mL plastic syringes 
that contained different concentrations of the SR-FLIVO-
FMNP sample (0.25–2 mg/mL in PBS) and 1 % gadoter-
ate meglumine (Magnescope, Terumo, Tokyo, Japan) as 
a standard of comparison. The MRI parameters of phan-
tom scanning were exactly the same as above.
Statistical analysis for cell counting and T2* signal intensity
ROIs in an area of 5 × 5 mm2 were determined on histo-
logical sections collected from the three studied groups 
(control, FMNP and SR-FLIVO-FMNP injected rats). 
SR-FLIVO-positive cells and TUNEL-positive cells were 
counted and the immunopositive ratios were calculated. 
The anatomically appropriate slice in scanned MRIs was 
selected and the voxels were determined according to 
the ROIs on the histological sections. Averaged reduc-
tion values in T2* signal intensity in each voxel were cal-
culated and compared with the immunopositive ratios. 
Correlations of these values were analyzed with Pearson 
correlative analysis and P values were calculated.
Results and discussion
Formation of SR‑FLIVO‑FMNP
A representative scheme (Fig.  1) is elucidated for the 
formation mechanism of FMNP and its conjugation to 
SR-FLIVO to form SR-FLIVO-FMNP probe. Charac-
terization using TEM, Fluorescence spectrophotometer 
and FTIR showed that; the average size of FMNP was 
determined to be 11.6 ± 0.6 nm and its surface could be 
successfully conjugated to SR-FLIVO with 80 % binding 
efficiency [31].
MRI signal intensity of SR‑FLIVO‑FMNP
To evaluate the magnetic property of the conjugated 
probe, we performed a phantom MRI experiment with 
SR-FLIVO-FMNP and 1  % gadoterate meglumine 
(Fig.  2). As expected, the higher concentration of SR-
FLIVO-FMNP showed relatively faster decay of MR 
signal intensity, whilst the lower concentration showed 
a slower decay of MR signal intensity. This result veri-
fied that the newly synthesized SR-FLIVO-FMNP probe 
possesses the magnetic contrast property in a concen-
tration-dependent manner. It should be noted that the 
influence of SR-FLIVO-FMNP on T2* reduction was 
relatively modest compared with that of a standard or 
commercially available contrast agent based on Fe3O4 
MNPs (Fig. 2). Since Fe2O3 is the most stable compound 
among the iron oxides and all other iron oxide forms get 
converted to Fe2O3 easily. Thus, it is expected to have a 
phase change due to the presence of reactive oxygen 
Fig. 1 A schematic illustration of the proposed formation mechanism of the core Fe2O3 MNP at SiO2 shell with −NH2 group-fictionalization to form 
FMNP and conjugation to SR-FLIVO to form SR-FLIVO-FMNP probe that is selectively interacting with activated caspases
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species accompanying apoptosis. However, the reported 
r2 of bare core Fe3O4 MNPs with comparable size is 
198  mM−1  S−1 whereas the estimated r2 for our bare 
core Fe2O3 MNPs is 42.8  mM−1 S−1 (Additional file  1). 
A higher effect of core Fe3O4 on T2 and T2* reduction 
could be expected and ascribed due to its higher magnet-
ization radius than Fe2O3 [33, 34].
Histological detection of apoptotic cells in rat brains 
after cerebral ischemia
Our study group has reported that TUNEL staining 
showed immunopositive cells in the penumbra region of 
ischemic rat brains within 24  h after reperfusion injury 
[30]. Intravenous administration of SR-FLIVO-FMNP 
induced intracellular accumulation of SR-FLIVO in 
apoptotic TUNEL-positive cells in the ischemic penum-
bra (Fig. 3).
TUNEL has arguably been the most common labeling 
method used for the identification of apoptotic cells. 
However, TUNEL cannot be used for living cells or ani-
mals since it requires permeabilization of the cell mem-
brane [14, 35, 36]. What has been attempted for imaging 
of apoptotic activity in patients or animals has typically 
involved radioactive labeling with annexin V and auto-
radiography or other complex imaging strategies using 
MRI [37, 38]. Annexin V has a benefit as an early marker 
of programmed cell death however, due to its very short 
plasma half life time (<5  min.), it is difficult to reliably 
detect its interaction since the time point of assessment 
can be critical. In addition, annexin V does not bind to 
all apoptotic tumor cells, and it also binds positively to 
normal and healthy bone marrow-derived cells [39– 41]. 
Furthermore, the inversion of phosphatidyl-serine may 
not be exclusively related to apoptosis [6, 7]. On the other 
hand, our developed probe has been allowed to be under 
blood circulation for 60 min. before MRI recording and 
our results confirmed existence of SR-FLIVO positivity 
within the ischemic lesion.
The proposed mechanism of the process could be 
explained based on the activation of caspases apoptosis, 
led to having a cysteine residue of these proteases as their 
active centers. SR-FLIVO as a main component in our 
probe has three segments; an inhibitor, which is selec-
tively binding the active center of the caspase; a reactive 
fluoromethylketone (FMK) segment which links irrevers-
ibly the thio-methyl ketone with the cysteine at the active 
center of caspase; and red sulforhodamine B segment as 
a fluorophore which helps in fluorescence detection of 
the cells that bound to the porbe. Selective binding could 
occur with the active rather than inactive caspases tak-
ing into account that they are labeling apoptotic cells. 
FLIVO includes the peptide-based, poly caspase-bind-
ing– inhibitor probe [Val-Ala-Asp(OMe)], which con-
tains an O-methylation moiety in the Aspartic residue 
that provides enhanced stability and cell permeability 
to the inhibitor. Since SR-FLIVO is cell permeant, thus; 
they can be i.v. injected into living rats, in which they 
can selectively bind to cells displaying active caspases, 
resulting in the trapping of the red SR-FLIVO fluores-
cence signal within these cells. FLIVO can’t give positive 
expression with non-apoptotic cells due to its leakage 
outside the cells that lack caspase activity [42].
Fig. 2 The concentration dependent results of the phantom MRI measurements (a). The averaged T2* quantities of SR-FLIVO-FMNP with standard 
deviation. Gd 1 % gadoterate meglumine (b)
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MRI of in vivo apoptosis in ischemic rat brains
A T2-weighted image revealed high intensity in the caudate 
putamen area supplied by the left MCA 24 h after ischemic 
reperfusion injury. SR-FLIVO-FMNP was intravenously 
injected and T2* mapping was scanned before and after 
the injection. Superparamagnetic iron oxide nanoparticles 
Fig. 3 Representative photographs of fluorescent images of SR-FLIVO (red, b, f) and TUNEL staining (green, c, g) on the non-ischemic side (a–d) 
and the ischemic side (e–h). The ROI is set in yellow squares in the non-ischemic area (a) and the ischemic area (e). Merged images of SR-FLIVO and 
TUNEL staining are shown in d and h. Almost no positive fluorescent expression was observed on the non-ischemic side (a–d). SR-FLIVO expression 
(f) and TUNEL immunopositivity (g) were observed in the region around the ischemic penumbra. Intracellular co-localization of these two immuno-
positivities can be detected in the merged image (orange, h). Bars 100 μm
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(SPION) was reported to show hypointensity in T2* map-
ping in rodent brains in vivo [20, 21, 23]. Vascular-rich tis-
sue such as choroid plexus showed T2* reduction induced 
by a slight non-specific uptake of iron nanoparticles as 
previously reported [43]. By subtracting images between 
pre- and post-injection, we calculated a T2* reduction area 
in the ischemic lesion without a non-specific uptake of iron 
particles in the background, as previously reported [44]. A 
T2* reduction region was observed around the ischemic 
core adjacent to the cortical area in ischemic rat brains after 
SR-FLIVO-MNP injection. No recorded T2* signal reduc-
tion was shown in bare FMNP-injection without conjuga-
tion of SR-FLIVO (Fig. 4).
MRI monitoring of molecular events in live cells in 
rodent brains has been previously reported. Varallyay 
et  al. [45] reported many promising results from the 
application of MNPs for MRI monitoring of a rat brain 
tumor model. Their group intravenously injected USPIO 
as passive targeting of a lesion that destroyed the BBB, 
as induced by a brain tumor, and detected iron oxide 
accumulation by 12T dynamic contrast-enhanced MRI 
fabricated superparamagnetic iron oxide nanoparticles 
(SPION)-glial fibrillary acidic protein (SPION-GFAP) 
probe for gene targeting in live brains. They adminis-
tered SPION-GFAP via the conjunctiva sac in rat cortical 
spreading depression models. SPION-GFAP was success-
fully accumulated in the β-actin-expressing region after 
permeation into the BBB and was detected by MRI as a 
T2* signal reduction region. These reports suggest the 
usefulness of MNPs for molecular MRI monitoring, and 
the future development of active targeting technology is 
strongly anticipated.
Surface-modified iron oxide MNPs could behave as con-
trast agents for facile targeting in MRI [46]. The biocom-
patibility of MNPs could be enhanced after careful study 
of the surface structures. This could allow facile shielding 
of the magnetic core with bio-polymers, which may lead 
to some extent to aggregation of the NPs, giving final prod-
ucts of larger sizes, or an inorganic silica shell that allows 
facile grafting to the surfaces and gives more stability to the 
MNP core against biodegradation when using various sol-
vent types and/or under physiological conditions [47]. Our 
new molecular design has been fabricated on the basis of 
the conjugation between the Fe2O3 MNP core grafted with 
thin silica shell functionalized with an amine group-NH2 
from one side and SR-FLIVO as a caspase inhibitor from 
the other side. To our knowledge, this is the first study to 
address such a molecular design for the biomedical appli-
cation for diagnosis of brain apoptotic lesions arising from 
brain transient cerebral ischemia. Bare Fe2O3 MNPs can 
be expected to have higher nano-toxicity however; surface 
coating of magnetic core using ad-layer synthesis led to hav-
ing a shield composed of hybrid inorganic–organic moieties 
(SiO2, −NH2 and SR-VAD-FMK) that are enhancing the 
stability and biocompatibility of the designed SR-FLIVO-
FMNP probe as a whole which possess slightly negative 
charge. (Additional file 1: Figure S2 represents the surface 
zeta potential of SR-FLIVO-FMNP probe which shows 
a sightly negative surface charge). Several studies dem-
onstrated that; NPs with mixed chemical structures have 
shown high compatibility including low hemolytic rates less 
than the cut-off limit (<5 %) increasing the opportunity of 
their application for in  vivo cellular tracking and imaging 
[48]. Nevertheless, Mocan et  al. [49] reported that; apop-
totic cells are recognized by macrophages equipped with 
receptors specific for phosphatidylserine such as Annexin V. 
The macrophages swoop and degrade phosphatidylserine-
exposing cells. Therefore, apoptosis allows the elimination 
of those cells without releasing of their intracellular proteins 
which could lead to inflammation. Contrary, erythrocytes 
lack nuclei and mitochondria which are the main in the 
apoptosis mechanism. Thus; the death of erythrocytes were 
considered to be eliminated by other mechanism nomi-
nated as eryptosis. Symptoms of both mechanisms could be 
quite similar however, apoptosis in erythrocytes is generally 
regarded as a mechanism that inhibits hemolysis and leads 
to a temporary stabilization of cells.
Histological evaluation of the T2* reduction region on MRI
We histologically examined the occurrence of apopto-
sis and iron accumulation in the ROI for the T2* reduc-
tion area after administration of SR-FLIVO-FMNP. No 
iron positivity was observed in the non-ischemic lesion. 
Electron microscopic findings showed intracellular SR-
FLIVO-FMNP deposition in apoptotic cells (Fig.  5). 
These findings of intracellular SR-FLIVO-FMNP depo-
sition were morphologically accordant with a previous 
report [50]. Intracellular SR-FLIVO expressions were 
prominently observed in TUNEL-positive cells in the 
ROI (Fig.  5). The frequency of SR-FLIVO or TUNEL 
immunopositivity was calculated in the ROI in the T2* 
signal reduction area. Correlation of the ratios of immu-
nopositivity and quantitative data of T2* signal reduction 
was analyzed (Fig. 6). The statistical evaluation revealed 
a significant linear correlation of T2* signal reduction to 
the ratio of SR-FLIVO immunopositive cells per square 
in the ROI (n =  33, r =  0.818, P < 0.0001) (Fig. 6). T2* 
signal reduction was also significantly correlated to the 
ratio of TUNEL immunopositivity per square in the 
ROI (n =  33, r =  0.801, P  <  0.0001) (Fig.  6). The aver-
age quantified distribution of positive % SR-FLIVO and 
% positive TUNEL was plotted for the three studied 
groups (control, FMNP and SR-FLIVO-FMNP injected 
ischemic rats). Significant positive distribution was found 
and co-localized with apoptotic positive TUNEL cells 
located within the ischemic lesion at rat brain tissues 
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for the SR-FLIVO-FMNP injected group (Fig. 7). Table 1 
summarizes the statistical data correlated to the histo-
logical evaluation. Significant co-localization percentage 
of 69.53  ±  9.95 suggests that; SR-FLIVO-FMNP probe 
could be used in addition to TUNEL staining protocol for 
the in/ex vivo apoptotic cells detection.
SR-FLIVO-FMNP probe was newly developed by con-
jugation of −NH2 functionalized Fe2O3 MNP at silica to 
Fig. 4 Representative magnetic resonance images of ischemic rat brains administered with bare FMNPs (a–d) and with SR-FLIVO-FMNPs (e–h). 
T2-weighted images (a, e), T2*-mappings of pre-injection (b, f), T2*-mappings of post-injection (c, g), and overlaid images of subtraction between 
before and after injection on T2-weighted images (d, h). There was no signal change between pre- and post-injection of bare MNPs (b, c). T2* signal 
reduction was prominently observed after injection of SR-FLIVO-FMNPs (f, g)
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SR-FLIVO [31]. Real system applicability of SR-FLIVO-
FMNP probe in the development of neuroradiological 
evaluation method could be achieved.
We demonstrated the following findings for the first 
time: (1) SR-FLIVO-FMNP was intravenously adminis-
tered into ischemic rats and FLIVO expression was found 
in apoptotic cells in rat brains after cerebral ischemia. (2) 
Injection of SR-FLIVO-FMNP lead to a remarkable T2* 
reduction in the ischemic brain, however, bare FMNP 
administration did not show a T2* reduction on MRI sub-
traction. (3) SR-FLIVO-FMNP probe accumulation was 
observed in apoptotic cells in the region of the T2* reduc-
tion and almost no probe accumulation were observed in 
non-apoptotic cells. (4) The findings of T2* reduction on 
Fig. 5 The ROI is set in a black square in the T2* signal reduction region (a). Fluorescent images of the ischemic brain section in the targeting area 
(b–d). SR-FLIVO expression (b) and TUNEL immunopositivity (c) were co-localized as shown in the merged image (d). Bar 20 μm. e–g Electron micro-
graphs demonstrated no localization of SR-FLIVO-FMNP probe inside control cell in non-ischemic core, whereas, it was localized within apoptotic 
cell in the ischemic core. Arrows point to the FMNP conjugated SR-FLIVO (g). Bar 500 nm for e and f and 100 nm for g
Fig. 6 Statistical data of correlation of T2* signal reduction with ratio of SR-FLIVO positivity and TUNEL positivity after SR-FLIVO-MNP administration. 
Linear relationships were observed between T2* signal reduction and SR-FLIVO (T2* reduction = 4.85 + 0.12 × % FLIVO positivity, n = 33, r = 0.818, 
P < 0.0001) (a). Linear relationships were observed between T2* signal reduction and TUNEL positivity (T2* reduction = 4.77 + 0.12 × % TUNEL 
positivity, n = 33, r = 0.801, P < 0.0001) (b)
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MRI subtraction in ischemic rat brains were significantly 
correlated to immunopositivities of TUNEL and FLIVO 
expression. Histological analysis showed that almost all 
FLIVO-positive cells were positive for TUNEL staining. 
The small discrepancy between FLIVO and TUNEL might 
be due to the difference in peak time points of activated 
caspases and DNA fragmentation. Iron accumulation after 
intravenous injection was non-specifically observed in 
the regions of vascular–rich tissue such as choroid plexus 
and inflammatory lesion [37]. The T2* reduction area in 
MRI included the contralateral paraventricular region 
to a small extent. However, our results showed limited 
non-specific accumulation. This could reflect the surface 
modification of iron oxide MNPs coated with functional-
ized silica shell, which might produce better biostability 
and contribute to less non-specific adhesion. The clear 
mechanisms of metabolism and circulatory dynamics after 
intravenous injection of SR-FLIVO-FMNP were of inter-
est as additional features. Our new findings shed the light 
on a new conjugated nanomaterial for MRI detection of 
apoptosis. These findings suggest the possibility of target-
ing delivery to live apoptotic cells and could contribute to 
the establishment of future methods for in vivo molecular 
imaging and noninvasive targeted delivery.
Conclusions
SR-FLIVO-FMNP was successfully delivered to apop-
totic cells in ischemic brains after intravenous admin-
istration and was shown to be an effective tool for MRI 
detection of in  vivo apoptosis. Targeting delivery with 
FMNPs conjugated with an enzyme or antibody might be 
effective for molecular MRI and for the development of 
a new cellular therapeutic strategy with high specificity. 
Multifunctional SR-FLIVO-FMNP has possibilities as a 
noninvasive imaging agent, for specific drug delivery and 
for intracellular tracking of targeting cells or adminis-
tered agents for live apoptotic lesions. Safe and effective 
multifunctional MNPs might contribute to molecular 
diagnosis at clinical examination and be highly targeted 
therapeutic tools in the future.
Authors’ contributions
ASa, MM and ASu conducted the experimental work and wrote the manu-
script. JR, HS, RK and TT contributed reagents/materials/analysis tools and 
gave advices to perform the needed experiments. All authors read and 
approved the final manuscript.
Author details
1 Department of Neurosurgery, Aomori Prefectural Central Hospital, 2-1-1 
Higashitsukurimichi, Aomori 030-8553, Japan. 2 Department of Neurosur-
gery, Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, 
Aoba-ku, Sendai, Miyagi 980-8575, Japan. 3 Department of Functional Brain 
Imaging, Institute of Development, Aging and Cancer, Tohoku University, 
2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. 4 Department 
of Neurosurgery, Graduate School of Medicine, Akita University, 1-1-1 Hondo, 
Akita 010-8543, Japan. 5 Present Address: National Institute for Materials Sci-
ence, 1-Chome-2-1 Sengen, Tsukuba, Ibaraki Prefecture 305-0047, Japan. 
Competing interests
The authors declare that they have no competing interests.
Received: 13 November 2015   Accepted: 26 February 2016
References
 1. Saito A, Narasimhan P, Hayashi T, Okuno S, Ferrand DM, Chan PH. Neuro-
protective role of a proline-rich Akt substrate in apoptotic neuronal cell 
death after stroke: relationships with nerve growth factor. J Neurosci. 
2004;24:1584–93.
 2. Schoenberger J, Bauer J, Moosbauer J, Eilles C, Grimm D. Innovative 
strategies in in vivo apoptosis imaging. Curr Med Chem. 2008;15:187–94.
 3. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, et al. Annixin 
A5-conjugated polymeric micelles for dual SPECT and optical detection 
of apoptosis. J Nucl Med. 2011;52:958–64.
Additional file
Additional file 1: Figure S1. Phantom MRI of conjugated SR-FLIVO-
FMNP showing T2 weighted signal reduction based on Fe concentration 
that was determined using Shimadzu atomic absorption spectrphotom-
eter AA-6200.
Fig. 7 Histological statistical analysis of average % TUNEL positivity 
and % SR-FLIVO positivity estimated from ischemic rat brain tissues, 
control, FMNP injected rats (group 2) and SR-FLIVO-FMNP injected rats 
(group 3). Significant average positivity of SR-FLIVO-FMNP injected 
group was observed compared with that in the bare FMNP injected 
and control groups (*P < 0.003)
Table 1 Statistical analysis of  %  TUNEL positivity, SR-
FLIVO positivity and  their co-localization estimated 









% TUNEL  
positivity
69.46 ± 8.78 72.08 ± 9.06 78.83 ± 10.22
% SR-FLIVO 
positivity
– – 86.50 ± 9.11
% Co-localized – – 69.53 ± 9.95
Page 11 of 11Saito et al. J Nanobiotechnol  (2016) 14:19 
 4. Dicker DT, Kim SH, Jin Z, El-Deiry WS. Heterogeneity in non-invasive 
detection of apoptosis among human tumor cell lines using annexin-V 
tagged with EGFP or Qdot-705. Cancer Biol Ther. 2005;4:1014–7.
 5. Dillon SR, Constantinescu A, Schlissel MS. Annexin V binds to positively 
selected B cells. J Immunol. 2001;166:58–71.
 6. Tait JF, Smith C, Wood BL. Measurement of phosphatidylserine exposure 
in leukocytes and platelets by whole-blood flow cytometry with annexin 
V. Blood Cells Mol Dis. 1999;25:271–8.
 7. Kim S, Bae SM, Seo J, Cha K, Piao M, Kim SJ, et al. Advantages of the phos-
phatidylserine-recognizing peptide PSP1 for molecular imaging of tumor 
apoptosis composed with annexin V. PLoS One. 2015;10(3):e0121171.
 8. Yivgi-Ohana N, Eifer M, Addadi Y, Neeman M, Gross A. Utilizing mitocondrial 
events as biomarkers for imaging apoptosis. Cell Death Dis. 2011;2:e166.
 9. Zhang M, Daniel AB, Louiza L, Bazabek D, Keven MB. Non-invasive 
detection of apoptosis using magnetic resonance imaging and targeted 
contrast agent. Nat Med. 2001;7:1241–4.
 10. Ye D, Shuhendler AJ, Pandit P, Brewer KD, Tee SS, Cui L, et al. Caspase-
responsive smart gadolinium-based contrast agent for magnetic reso-
nance imaging of drug-induced apoptosis. Chem Sci. 2014;5:3845–52.
 11. Andrew JS, Gavin DK, Jenny DB, Duncan RC, Ramon V. Targeting of ani-
onic membrane species by lanthanide (III) complexes towards improved 
MRI contrast agents for apoptosis. Chem Comm. 2011;47:10245–7.
 12. Dash R, Chung J, Chan T, Yamada M, Barral J, Nishimura D, Yang CP, Simp-
son PC. A molecular MRI probe to detect treatment of cardiac apoptosis 
in vivo. Magn Reson Med. 2011;66:1152–62.
 13. Tilborg G, Vucic E, Strijkers GJ, Cormode PD, Mani V, Skajaa T, Reuteling-
sperger CP, Fayad ZA, et al. Annexin A5-functionalized bimodal nano-
particles for MRI and fluorescence imaging of atherosclerotic plaques. 
Bioconjug Chem. 2010;21:1794–803.
 14. Griffin RJ, Williams BW, Bischof JC, Olin M, Johnson GL, Lee BW. Use of 
a fluorescently labeled poly-caspase inhibitor for in vivo detection of 
apoptosis related to vascular-targeting agent arsenic trioxide for cancer 
therapy. Technol Cancer Res Treat. 2007;6:651–4.
 15. Cursio R, Colosetti P, Auberger P, Gugenheim J. Liver apoptosis following 
normothermic ischemia-reperfusion: in vivo evaluation of caspase activ-
ity by FLIVO assay in rats. Transpl Proc. 2008;40:2038–41.
 16. Park S, Yamaguchi M, Zhou C, Calvert JW, Tang J, Zhang JH. Neurovascular 
protection reduces early brain injury after subarachnoid hemorrhage. 
Stroke. 2004;35:2412–7.
 17. Bedner E, Smolewski P, Amstad P, Darzynkiewicz Z. Activation of caspases 
measured in situ by binding of fluorochrome-labeled inhibitors of 
caspases (FLICA): correlation with DNA fragmentation. Exp Cell Res. 
2000;259:308–13.
 18. Hartman KB, Wilson LJ, Rosenblum MG. Detecting and treating cancer 
with nanotechnology. Mol Diagn Ther. 2008;12:1–4.
 19. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson 
L. Ultrasmall superparamagnetic iron oxide: characterization of a new 
class of contrast agents for MR imaging. Radiology. 1990;175:489–93.
 20. Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney 
WD, et al. Superparamagnetic iron oxide nanoparticles: diagnostic 
magnetic resonance imaging and potential therapeutic applications in 
neurooncology and central nervous system inflammatory pathologies, a 
review. J Cereb Blood Flow Metab. 2010;30:15–35.
 21. Kyle S, Saha S. Nanotechnology for the detection and therapy of stroke. 
Adv Healthc Mater. 2014;3:1–19.
 22. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide 
nanoparticle probes for molecular imaging. Ann Biomed Eng. 2009;34:23–38.
 23. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, et al. 
Comparison of two superparamagnetic viral-sized iron oxide particles 
ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging 
intracranial tumors. AJNR Am J Neuroradiol. 2002;23:510–9.
 24. Lee CM, Jeong HJ, Kim EM, Kim DW, Lim ST, Kim HT, Park IK, et al. 
Superparamagnetic iron oxide nanoparticles as a dual imaging probe for 
targeting hepatocytes in vivo. Magn Reson Med. 2009;62:1440–6.
 25. Lee H, Lee E, do Kim K, Jang NK, Jeong YY, Jon S. Antibiofouling polymer-
coated superparamagnetic iron oxide nanoparticles as potential mag-
netic resonance contrast agents for in vivo cancer imaging. J Am Chem 
Soc. 2006;128:7383–9.
 26. Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A. Magnetic resonance relaxa-
tion properties of superparamagnetic particles. Wiley Interdiscip Rev 
Nanomed Nanobiotechnol. 2009;1:299–310.
 27. Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on sur-
face engineering of magnetic iron oxid nanoparticles and their biomedi-
cal applications. Nanomedicine. 2007;2:23–9.
 28. Kuhlpeter R, Dahnke H, Matuszewski L, Persigehl T, Von Wallbrunn A, 
Allkemper T, et al. R2 and R2* mapping for sensing cell-bound superpara-
magnetic nanoparticles: in vitro and murine in vivo testing. Radiology. 
2007;245:449–57.
 29. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral 
artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.
 30. Okuno S, Saito A, Hayashi T, Chan PH. The c-Jun N-terminal protein kinase 
signaling pathway mediates Bax activation and subsequent neuronal 
apoptosis through interaction with Bim after transient focal cerebral 
ischemia. J Neurosci. 2004;24:7879–87.
 31. Mekawy M, Saito A, Shimizu H, Tominaga T. Targeting of apoptotic cells 
using functionalized Fe2O3 nanoparticles. Nanomaterials. 2015;5:874–84.
 32. Sumiyoshi A, Riera JJ, Ogawa T, Kawashima R. A mini-cap for simultane-
ous EEG and fMRI recording in rodents. NeuroImage. 2011;54:1951–65.
 33. Taboada E, Solanas R, Rodriguez E, Weissleder R, Roig A. Supercritical-
Fluid-assisted one-pot synthesis of biocompatible Core(g-Fe2O3)/
Shell(SiO2) nanoparticles as high relaxivity T2-contrast agents for mag-
netic resonance imaging. Adv Func Mater. 2009;19:2319–24.
 34. Mohapatra A, Mitra A, Aslam M, Bahadour D. Octahedral-shaped Fe3O4 
nanoparticles with enhanced specific absorption rate and R2 relaxivity. 
IEEE Trans Magn. 2015;51:11.
 35. Allen RT, Hunter WJ, Agrawal DK. Morphological and biochemical 
characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 
1997;37:215–28.
 36. Sasano H, Yamaki H, Nagura H. Detection of apoptotic cells in cytology 
specimens: an application of TdT-mediated dUTP-biotin nick end labeling 
to cell smears. Diagn Cytopathol. 1998;18:398–402.
 37. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, 
et al. In vivo detection and imaging of phosphatidylserine expression 
during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349–54.
 38. Papaevangelou E, Almeida GS, Jamin Y, Robinson SP, deSouza NM. Diffu-
sion-weighted MRI for imaging cell death after cytotoxic or apoptosis-
inducing therapy. British J Cancer. 2015;112:1471–9.
 39. Watanabe H, Murata Y, Miura M, Hasegawa M, Kawamoto T, Shibuya H. 
In-vivo visualization of radiation-induced apoptosis using (125)I-annexin 
V. Nucl Med Commun. 2006;27:81–9.
 40. Dicker DT, Kim SH, Jin Z, El-Deiry WS. Heterogeneity in non-invasive 
detection of apoptosis among human tumor cell lines using annexin-V 
tagged with EGFP or Qdot-705. Cancer Biol Ther. 2005;4:1014–7.
 41. Dillon SR, Constantinescu A, Schlissel MS. Annexin V binds to positively 
selected B cells. J Immunol. 2001;166:58–71.
 42. Laura GC, Cristina DM, Pilar LC, Cristina ED, Luis AC, Lorena RB, et al. 
Detecting apoptosis of leukocytes in mouse lymph nodes. Nat Protocol. 
2014;9:1102–12.
 43. Wiart M, Davoust N, Pialat JB, Desestret V, Moucharrafie S, Cho TH, et al. 
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke. 
2007;38:131–7.
 44. Liu CH, You Z, Ren J, Kim YR, Eikermann-Haerter K, Liu PK. Noninvasive 
delivery of gene targeting probes to live brains for transcription MRI. 
FASEB J. 2008;22:1193–203.
 45. Varallyay CG, Muldoon LL, Gahramanov S, Wu YJ, Goodman JA, Li X, et al. 
Dynamic MRI using iron oxide nanoparticles to assess early vascular 
effects of antiangiogenic versus corticosteroid treatment in a glioma 
model. J Cereb Blood Flow Metab. 2009;29:853–60.
 46. Moore A, Marcecos E, Bogdanov A, Weissleder R. Tumoral distribution 
of long-circulating dextran-coated iron oxide nanoparticles in a rodent 
model. Radiology. 2000;214:568–74.
 47. Arruebo M, Ho WY, Lam KF, Chen X, Arbiol J, Santamaria J, et al. Prepara-
tion of magnetic nanoparticles encapsulated by an ultrathin silica shell 
via transformation of magnetic Fe-MCM-41. Chem Mater. 2008;20:486–93.
 48. Wu W, He Q, Jiang C. Magnetic iron oxide nanoparticles: synthesis and 
surface functionalization strategies. Nanoscale Res Lett. 2008;3:397–415.
 49. Mocan T. Hemolysis as expression of nanoparticles-induced cytotoxicity 
in red blood cells. Biotechnol Mol Biol Nanomed. 2013;1:7–12.
 50. Jendelová P, Herynek V, Urdziková L, Glogarová K, Kroupová J, Andersson 
B, et al. Magnetic resonance tracking of transplanted bone marrow and 
embryonic stem cells labeled by iron oxide nanoparticles in rat brain and 
spinal cord. J Neurosci Res. 2004;76:232–43.
